NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESATI-1501, liquid oral reformulation of the antibiotic metronidazole, receives PDUFA action date of September 23, 2023.HALIFAX, Nova Scotia (BUSINESS WIRE) Appili Therapeutics Inc. (TSX: APLI) (the “Company” or “Appili”.
17.01.2023 - Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, has named Carl Gelhaus, Ph.D., as Director of Non-Clinical Research, and .
Appili Therapeutics Appoints Dr Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Appili Therapeutics Announces Notice of Allowance from the U S Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Dr. Armand Balboni appointed as Chair of the Board and moves to the U.S. Air Force Academy to take over as Principal Investigator for the ATI-1701 program; and Dr. Don Cilla promoted to President and. | November 14, 2022